Immunoglobulin A nephropathy with mild renal lesions: A call in the forest for physicians and nephrologists

American Journal of Medicine

Volumn 110, Issue 6, 2001, Pages 499-500

  Schena, Francesco Paolo ^a  

^a Division of Nephrology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTEIN;

BLOOD PRESSURE MONITORING; EDITORIAL; FOLLOW UP; HEMATURIA; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY INJURY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN URINE LEVEL; PROTEINURIA;

GLOMERULONEPHRITIS, IGA; HEMATURIA; HUMANS; KIDNEY FAILURE, CHRONIC; PROGNOSIS; PROTEINURIA;

EID: 0035870773     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)00684-2     Document Type: Editorial

References (7)

1. Schena F.P. A retrospective analysis of the natural history of primary IgA nephropathy worldwide. Am J Med. 89:1990;209-215.
2. D'Amico G. Natural history of idiopathic IgA nephropathy role of clinical and histological prognostic factors . Am J Kidney Dis. 36:2000;227-237.
3. Szeto C-C, Lai F M-M, To K-F, et al. Natural history of IgA nephropathy presenting with hematuria and minimal proteinuria. Am J Med. 2001;110:434-437.
4. Maschio G., Albert D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 334:1996;939-945.
5. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 349:1997;1857-1863.
6. Ruggenenti P., Perna A., Gherardi G., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 354:1999;359-364.
7. Giatras I., Lau J., Levey A.S. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease a meta-analysis of randomized trials. Angiotensin-converting-enzyme inhibition and progressive renal disease study group . Ann Intern Med. 127:1997;337-345.